Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 8 studies | 29% ± 10% | |
oligodendrocyte precursor cell | 4 studies | 26% ± 5% | |
Schwann cell | 3 studies | 40% ± 19% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 31% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 94% | 765.53 | 2474 / 2642 | 100% | 8.33 | 702 / 705 |
skin | 31% | 70.18 | 562 / 1809 | 93% | 29.32 | 440 / 472 |
blood vessel | 97% | 1233.30 | 1295 / 1335 | 0% | 0 | 0 / 0 |
heart | 75% | 292.01 | 650 / 861 | 0% | 0 | 0 / 0 |
intestine | 67% | 347.76 | 646 / 966 | 9% | 0.16 | 45 / 527 |
esophagus | 54% | 178.87 | 786 / 1445 | 17% | 0.45 | 32 / 183 |
eye | 0% | 0 | 0 / 0 | 68% | 5.15 | 54 / 80 |
breast | 21% | 64.81 | 98 / 459 | 38% | 4.77 | 429 / 1118 |
stomach | 28% | 91.40 | 102 / 359 | 14% | 0.23 | 39 / 286 |
adrenal gland | 10% | 21.24 | 26 / 258 | 29% | 1.07 | 66 / 230 |
prostate | 31% | 97.11 | 77 / 245 | 2% | 0.03 | 9 / 502 |
pancreas | 0% | 0.70 | 1 / 328 | 30% | 0.66 | 54 / 178 |
thymus | 2% | 5.15 | 13 / 653 | 28% | 0.65 | 168 / 605 |
uterus | 15% | 37.29 | 26 / 170 | 13% | 0.33 | 60 / 459 |
bladder | 14% | 28.67 | 3 / 21 | 9% | 0.42 | 47 / 504 |
lung | 2% | 3.42 | 11 / 578 | 16% | 0.39 | 185 / 1155 |
adipose | 16% | 46.95 | 194 / 1204 | 0% | 0 | 0 / 0 |
ovary | 9% | 23.56 | 16 / 180 | 2% | 0.07 | 9 / 430 |
lymph node | 0% | 0 | 0 / 0 | 10% | 0.14 | 3 / 29 |
kidney | 2% | 4.45 | 2 / 89 | 6% | 0.10 | 54 / 901 |
liver | 0% | 0 | 0 / 226 | 7% | 0.20 | 29 / 406 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.15 | 2 / 45 |
muscle | 4% | 6.27 | 29 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 1.60 | 8 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006915 | Biological process | apoptotic process |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0010468 | Biological process | regulation of gene expression |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0048863 | Biological process | stem cell differentiation |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0005886 | Cellular component | plasma membrane |
GO_0045211 | Cellular component | postsynaptic membrane |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0005515 | Molecular function | protein binding |
GO_0030971 | Molecular function | receptor tyrosine kinase binding |
Gene name | SHC4 |
Protein name | SHC adaptor protein 4 SHC-transforming protein 4 (Rai-like protein) (RaLP) (SHC-transforming protein D) (hShcD) (Src homology 2 domain-containing-transforming protein C4) (SH2 domain protein C4) |
Synonyms | UNQ6438/PRO21364 SHCD |
Description | FUNCTION: Activates both Ras-dependent and Ras-independent migratory pathways in melanomas. Contributes to the early phases of agrin-induced tyrosine phosphorylation of CHRNB1. . |
Accessions | ENST00000537958.5 ENST00000557797.5 H0YLZ2 ENST00000558220.1 H0YLU6 F5H5M1 ENST00000332408.9 [Q6S5L8-1] ENST00000396535.7 [Q6S5L8-2] Q6S5L8 |